On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer in patients whose disease has not progressed immediately following platinum-based chemotherapy .1 Rates of lung cancer in Scotland are among the highest in the world2 and are significantly higher in Scotland compared with the other UK countries for both men and women3. “Acceptance for use from the SMC is good news for Scottish patients and brings the available treatment options in line with those in England” said Phil Knott, Head of Oncology for Lilly UK.
